Taking multiple "points" (100mg doses) in a single session is extremely common among enjoyers of MDMA.
People don't really build tolerance to MDMA when they use it responsibly.
This is a phase 3 clinical trial, aka the last and most rigorous phase before potential FDA approval. There have already been studies previous to this one that establish safe bounds for dosage of chemically pure MDMA in a clinical setting, many of which are targeted at patients with "no tolerance" (aka drug naïve).
You are clutching pearls pretty hard here. Experimental medicine is not without risks. Apparently 8 whole active study group participants (less than 10%) experienced mild tachycardia, aka fast heartbeat, in a setting full of trained medical professionals with the skills and equipment to handle such events. There was also some sweating and nervousness. Compare that to a moderate to bad episode of PTSD and it's a walk in the park by comparison. This is highly ethical research. Take a breath and carefully read the full study and some of its references, as well as some other ones prior to this phase 3 trial, if you are seriously concerned about this issue.
> Taking multiple "points" (100mg doses) in a single session is extremely common among enjoyers of MDMA.
300mg, especially for someone without prior MDMA experience, is an absolutely unhinged hero dose.
300mg spaced out over the course of 12 hours or so is somewhat less so, but you absolutely will get fewer effects on re-dosing, and fewer the next day as well if you dose again.
That said 120mg should be pretty safe for anyone, but with lower-tolerance or lighter users, could definitely reduce their ability to engage in meaningful conversation or retain any memory of what they discussed.
Which isn't to say they won't come away from the experience feeling warm fuzzies and possibly with significant improvements in their PTSD symptoms, but it does make me wonder if it's a good way to study how much of that is the talk therapy and how much is just the therapeutic effects of the drug
From the article:
The treatment period consisted of three 8-h dosing sessions, in conjunction with therapy, spaced approximately 1 month apart.